复星医药
(600196)
| 流通市值：504.20亿 | | | 总市值：635.78亿 |
| 流通股本：21.18亿 | | | 总股本：26.71亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 30,911,889,002.9 | 20,462,812,731.15 | 10,157,255,262.4 | 41,399,539,588.42 |
| 营业收入 | 30,911,889,002.9 | 20,462,812,731.15 | 10,157,255,262.4 | 41,399,539,588.42 |
| 二、营业总成本 | 29,362,812,762.85 | 19,408,879,676.26 | 9,522,433,489.91 | 41,284,076,914.38 |
| 营业成本 | 15,889,599,601.5 | 10,463,385,539.56 | 5,077,706,398.06 | 21,595,308,756.94 |
| 税金及附加 | 233,828,884.22 | 164,222,484.23 | 92,441,739.26 | 271,255,381.04 |
| 销售费用 | 6,592,219,720.43 | 4,266,270,759.14 | 2,240,230,894.06 | 9,712,237,437.28 |
| 管理费用 | 3,144,563,560.08 | 2,064,431,733.81 | 1,002,269,117.88 | 4,374,907,225.8 |
| 研发费用 | 2,648,036,346.49 | 1,861,735,885.19 | 829,567,181.62 | 4,346,044,722.61 |
| 财务费用 | 854,564,650.13 | 588,833,274.33 | 280,218,159.03 | 984,323,390.71 |
| 其中:利息费用 | 1,067,876,593.66 | 709,545,120.01 | 348,094,758.07 | 1,324,830,525.62 |
| 其中:利息收入 | 279,711,179.34 | 188,969,456.09 | 99,674,904.3 | 363,645,386.22 |
| 加:公允价值变动收益 | -106,245,847.25 | -282,397,883.66 | -20,137,300.33 | -427,379,582.37 |
| 加:投资收益 | 1,498,762,805.9 | 1,061,766,335.39 | 335,558,032.75 | 3,501,992,600.27 |
| 资产处置收益 | 2,513,587.58 | 716,943.9 | 434,102.64 | 5,563,773.63 |
| 资产减值损失(新) | -40,946,606.35 | -20,173,454.3 | 5,885,553.46 | -219,742,228.92 |
| 信用减值损失(新) | -54,465,502.75 | -38,037,746.1 | -16,414,132.84 | -131,927,327.75 |
| 其他收益 | 258,894,140.64 | 153,479,541.53 | 81,216,032.81 | 463,537,996.22 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 3,107,588,817.82 | 1,929,286,791.65 | 1,021,364,060.98 | 3,307,507,905.12 |
| 加:营业外收入 | 34,567,912.8 | 28,856,541.36 | 9,314,129.85 | 57,124,008.22 |
| 减:营业外支出 | 70,590,845.22 | 26,942,539.67 | 12,254,333.74 | 100,064,034.6 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 3,071,565,885.4 | 1,931,200,793.34 | 1,018,423,857.09 | 3,264,567,878.74 |
| 减:所得税费用 | 553,048,247.94 | 381,468,816.23 | 232,202,701.23 | 369,504,452.16 |
| 六、净利润 | 2,518,517,637.46 | 1,549,731,977.11 | 786,221,155.86 | 2,895,063,426.58 |
| 持续经营净利润 | 2,518,517,637.46 | 1,549,731,977.11 | 786,221,155.86 | 2,895,063,426.58 |
| 归属于母公司股东的净利润 | 2,010,642,360.52 | 1,224,798,594.42 | 609,733,627.26 | 2,386,265,813.74 |
| 少数股东损益 | 507,875,276.94 | 324,933,382.69 | 176,487,528.6 | 508,797,612.84 |
| (一)基本每股收益 | 0.75 | 0.46 | 0.23 | 0.89 |
| (二)稀释每股收益 | 0.75 | 0.46 | 0.23 | 0.89 |
| 八、其他综合收益 | -213,927,299.31 | 112,419,919.18 | 91,154,209.97 | 31,857,159.28 |
| 归属于母公司股东的其他综合收益 | -177,247,663.14 | 96,538,158.48 | 75,499,446.89 | -35,442,050.43 |
| 九、综合收益总额 | 2,304,590,338.15 | 1,662,151,896.29 | 877,375,365.83 | 2,926,920,585.86 |
| 归属于母公司股东的综合收益总额 | 1,833,394,697.38 | 1,321,336,752.9 | 685,233,074.15 | 2,350,823,763.31 |
| 归属于少数股东的综合收益总额 | 471,195,640.77 | 340,815,143.39 | 192,142,291.68 | 576,096,822.55 |
| 公告日期 | 2024-10-30 | 2024-08-28 | 2024-04-30 | 2024-03-27 |
| 审计意见(境内) | | | | 标准无保留意见 |